Safety And Efficacy Of L-Arginine Monotherapy Versus Tadalafil Monotherapy Versus Their Combination In Men With Erectile Dysfunction; A Prospective Randomized Study
Key facts
- Who runs it
- Fayoum University Hospital
- Where
- Egypt1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 180 people enrolled
- Started
- 14 Jan 2024
- Ended
- 1 Feb 2025
- Type of study
- Interventional, 3 groups
- Treatments tested
- L-Arginine
- Tadalafil 5 mg
- Record updated
- 27 April 2025
Who can take part
- Age
- 45 years to 75 years
- Sex
- Men only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- • Naive ( not previously treated) male patient with mild to moderate ED according to SHIM Questionnaire
Who cannot take part
- ● Kidney disease or liver failure; Coronary heart disease; Peyronie's disease; Neurological disease that may related to ED
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Introduction Sexual dysfunctions are annoying health problems with the erectile problems forming the main part of them. Erectile dysfunction (ED) is defined as the persistent inability to obtain or maintain an erection that is sufficient to allow satisfactory sexual intercourse.[1] Aim of Work To evaluate the role of L-arginine monotherapy versus Tadalafil monotherapy versus their combination for the treatment of erectile dysfunction .
Read full original descriptionShow less
Patients and methods:
Inclusion criteria:
• Naive ( not previously treated) male patient with mild to moderate ED according to SHIM Questionnaire.
Exclusion criteria:
* Kidney disease or liver failure * Coronary heart disease * Peyronie's disease * Neurological disease that may related to ED
The 3 groups in the trial
- Group ATreatment being tested
was given daily 3 g(three divided doses) oral tablets of L-arginine for eight weeks
Treatment: L-Arginine
- Group BTreatment being tested
was given daily 5 mg oral tablets of Tadalafil for eight weeks.
Treatment: Tadalafil 5 mg
- Group CTreatment being tested
was given daily 3 g oral tablets of L-arginine and 5 mg oral tablets of Tadalafil for eight weeks.
Treatment: L-Arginine and Tadalafil 5 mg
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 27 April 2025